| abstract |
Disclosed is a composition for treating major depressive disorder, characterized by comprising a buprenorphine active ingredient and a dextromethorphan active ingredient. The weight ratio of the buprenorphine active ingredient to the dextromethorphan active ingredient is 1:7.5-300. By means of synergistic compounding of the buprenorphine and the dextromethorphan, the present invention acts to stimulate a μ-opioid receptor, antagonize a κ-opioid receptor, antagonize an NMDA receptor, stimulate a sigma-1 receptor, antagonize a 5-HT receptor and an NE receptor, and to block an inflammatory pathway, etc. to achieve combined effects of multiple targets and multiple mechanisms, making it possible to greatly improve therapeutic effects on patients with major depressive disorder (MDD), especially treatment-resistant depression (TRD). Furthermore, the dextromethorphan reduces the dosage and addictiveness of the buprenorphine, achieving the advantages of multiple targets, rapid onset, and low addictiveness. |